Mr Richard Allen

Clinical Medicine, School of Medicine and Population Health

Technical Team Leader

r.j.allen@sheffield.ac.uk
+44 114 215 9027

EU24, E Floor, Royal Hallamshire Hospital

Full contact details

Mr Richard Allen
Clinical Medicine, School of Medicine and Population Health
EU24, E Floor
Royal Hallamshire Hospital
Glossop Road
Sheffield
S10 2JF

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Juncker-Jensen A, Stavrou N, Moamin M, Nagy M, Allen R, Cox A & Lewis C (2021) 828 Quantifying perivascular immune cells in the stroma of human triple negative breast tumors using deep learning spatial analytics. Journal for ImmunoTherapy of Cancer, 9(Suppl 2), A867-A867.
Kwan A, Winder N, Atkinson E, Al-Janabi H, Allen RJ, Hughes R, Moamin M, Louie R, Evans D, Hutchinson M , Capper D et al (2021) Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. Molecular Cancer Therapeutics, 20(3), 589-601.
Bishop RT, Marino S, Carrasco G, Li B, Allen RJ, Sparatore A, Ottewell PD, Mollat P, Sims AH, Capulli M , Wang N et al (2020) Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis. Cancer Letters, 488, 27-39.
Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD & Idris AI (2019) Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer. Cancer Letters, 450, 76-87. View this article in WRRO
Moamin MR, Allen R, Woods SL, Brown JE, Nunns H, Juncker-Jensen A & Lewis CE () Changes in the immune landscape of TNBC after neoadjuvant chemotherapy: correlation with relapse. Frontiers in Immunology, 14.
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al () Macrophage Delivered HSV1716 Is Active against Triple Negative Breast Cancer. Future Pharmacology, 2(4), 444-459.
Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, Helleday T, Hullock K, Pennington CEW, Rantala J , Collis SJ et al () Precision oncology using ex vivo technology: a step towards individualised cancer care?. Expert Reviews in Molecular Medicine, 1-48.

Conference proceedings papers

Gagg H, Williams S, Allen R, Conroy S, Rominiyi O, Wells G, Rantala J, Danson S, Helleday T & Collis S (2022) Ex vivo-led drug discovery in glioblastoma. WFNOS 2022 Abstract Book, 24 March 2022 - 27 March 2022.
Moamin MR, Allen RJ, Stavrou N, Nagy M, Juncker-Jensen A & Lewis CE (2021) Abstract 2720: Perivascular accumulation of immunosuppressive cells in the stroma of human triple negative breast carcinomas: implications for immunotherapy. Cancer Research, Vol. 81(13_Supplement) (pp 2720-2720)